ENTERIC COATED DAILY LOW DOSE ASA 81 MG TABLET (DELAYED-RELEASE)

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

ACETYLSALICYLIC ACID

Доступна з:

VITA HEALTH PRODUCTS INC

Код атс:

B01AC06

ІПН (Міжнародна Ім'я):

ACETYLSALICYLIC ACID

Дозування:

81MG

Фармацевтична форма:

TABLET (DELAYED-RELEASE)

Склад:

ACETYLSALICYLIC ACID 81MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

30/120/180/300

Тип рецепту:

OTC

Терапевтична области:

SALICYLATES

Огляд продуктів:

Active ingredient group (AIG) number: 0101169013; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2011-02-17

Характеристики продукта

ASA 81 mg Page 1 of 46
PRODUCT MONOGRAPH
ASA 81 MG
Acetylsalicylic Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
Vita Health Products Inc.
150 Beghin Avenue
Winnipeg, MB
Canada R2J 3W2
Control Number: 261087
Date of Preparation:
February 3, 2011
Date of Revision :
March 23, 2022
ASA 81 mg Page 2 of 46
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................................................
4
ADVERSE REACTIONS
...............................................................................................................
7
DRUG INTERACTIONS
...............................................................................................................
7
DOSAGE AND ADMINISTRATION
...........................................................................................
9
OVERDOSAGE
...........................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
11
STORAGE AND STABILITY
.....................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
14
PHARMACEUTICAL INFORMATION
.....................................................................................
14
CLINICAL TRIALS
..............